Sampo has filed an application to extend the Group's Partial Internal Model
Sampo has filed an application to extend the Group's Partial Internal Model
Advertisement
Following the legal merger of If and Topdanmark on 1 July 2025, Sampo has filed an application to the Swedish FSA (Finansinspektionen) to extend the Group's Partial Internal Model to include the operations formerly under Topdanmark. Sampo expects that the application process will be completed in late 2025 or early 2026 at the latest.
Sampo estimates that the extended model could reduce the group-level solvency capital requirement by around EUR 60-90 million.
SAMPO PLC
Investor Relations and Group Communications
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Verkkokauppa.com Oyj: Composition of the Shareholders' Nomination Board
Oyj STOCK EXCHANGE RELEASE 12 August 2025 at 17:30 EEST Oyj: Composition of the Shareholders' Nomination Board The Annual General Meeting of Oyj resolved on 31 March 2020 to establish a Shareholders' Nomination Board. The Nomination Board consists of the Company's three largest shareholders or persons nominated by such shareholders. The right to nominate members is determined based on the shareholding on the last working day of May preceding the Annual General Meeting. The Chair of the Board is an expert member of the Nomination Board. The members of Nomination Board are: Samuli Seppälä, Founder of representing himself, Erkka Kohonen, Senior Portfolio Manager, nominated by Varma Mutual Pension Insurance Company, and Janne Kujala, Head of Nordic Equities, nominated by Evli Fund Management Company Ltd. At its organizational meeting on 12 August 2025, the Nomination Board elected Erkka Kohonen as its Chair. Arja Talma, Chair of the Board of Oyj, acts as an expert member of the Nomination Board. The Shareholders' Nomination Board prepares proposals on the number, election, and remuneration of the members of the Board to the General Meeting. The Nomination Board shall submit its proposal to the Board every year by the last business day of February preceding the next Annual General Meeting. For more information, please contact: Erkka Kohonen Chair of the Shareholders' Nomination Board Tel. +358 10 309 5555 Arja Talma Chair of the Board of Oyj Tel. +358 10 309 5555 Klaus Korhonen, Head of Legal Tel. +358 50 32 555 28 is an e-commerce pioneer that stands passionately on the customer's side. accelerates the transition of commerce to online with Finland's fastest deliveries and ultimate convenience. The company leads the way by offering one-hour deliveries to more than 1.7 million customers, a winning assortment and probably always cheaper prices. Every day, the company strives to find more streamlined ways to surpass its customers´ expectations and to create a new norm for buying and owning. was founded in 1992 and has been online since day one. The company's revenue in 2024 was EUR 468 million and it employs around 600 people. is listed on the Nasdaq Helsinki stock exchange.
Yahoo
2 hours ago
- Yahoo
Aspo to publish its Half-year Financial Report for January-June 2025 on Monday, August 18, 2025
Aspo Plc Press Release August 12, 2025 at 5.30 p.m. Aspo to publish its Half-year Financial Report for January-June 2025 on Monday, August 18, 2025 Aspo Plc will publish Half-year Financial Report for January-June 2025 on Monday, August 18, 2025, at approximately 9.00 a.m. EEST. News conference for analysts, investors and media will be held at Sanomatalo, Flik Studio Eliel, Töölönlahdenkatu 2, Helsinki on August 18, 2025, at 12.00 p.m. The event is also open to private investors, and participants are requested to register beforehand by emailing viestinta@ The half-year financial report will be presented by CEO Rolf Jansson and CFO Erkka Repo. The event will be held in English, and it can also be followed as a live webcast at Questions can be asked through conference call connection and webcast form. In order to receive the phone numbers and a identifier for the conference call, participants are requested to register using this link: A recording of the event will be available later the same day on the company's website For further information, please contact: Susanna Hietanen, Communications Director, Aspo Plc, tel. +358 50 3595 701, creates value by owning and developing business operations sustainably and in the long term. Aspo's businesses – ESL Shipping, Telko and Leipurin – enable future-proof, sustainable choices for customers in various industries. Established in 1929, today we are together about 800 experts on land and at sea. While the Nordic region is our core market, we serve our customers with world-class solutions in 18 countries around Europe and parts of Asia. Aspo is listed on Nasdaq Helsinki and is headquartered in Finland. Aspo – Sustainable value creationSign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Xspray Pharma Signs License Agreement with Handa Therapeutics – to Receive up to Double-Digit Royalty on Handa's Net Proceeds
Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization of a dasatinib product in the US market and, at a later stage, selected Asian markets. Under the agreement, Xspray will receive up to a double-digit royalty on Handa's net proceeds. STOCKHOLM, August 12, 2025--(BUSINESS WIRE)--This is the first out-licensing from Xspray's broad patent portfolio and marks an important milestone in capitalizing on its intellectual property assets. The company's core strategy to develop and commercialize improved PKI-drugs using its patented HyNap technology remains unchanged. Its lead product candidate Dasynoc awaits FDA-approval with a PDUFA date of October 7, 2025. However, further licensing agreements may be considered on a case-by-case basis. "The agreement confirms the value of our patent portfolio and demonstrates that our long-term work to build our comprehensive patent portfolio is paying off. As for the dasatinib market, I'm convinced that when Dasynoc is launched it will be seen as the premium product in its market segment as it combines pH-independent absorption with lower dose strength and high precision, eliminating sensitivity to all acid-reducing agents," says Per Andersson, CEO of Xspray Pharma. The agreement further ensures that Xspray's planned launch of Dasynoc can proceed without being affected by any United States regulatory exclusivities that may be associated with Handa's product. Handa's dasatinib product has not yet been launched. About Xspray Pharma Xspray Pharma AB (publ) is a pharmaceutical company focused on the development of improved PKIs for cancer treatment, leveraging its proprietary HyNap™ technology platform. The company aims to enhance clinical outcomes for cancer patients by improving the efficacy, safety, and patient experience of existing cancer therapies. Xspray Pharma's shares are traded at Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY). For more information about Xspray Pharma AB and its innovative approach to cancer treatment, please visit View source version on Contacts For further information, please contact: Jacob Nyberg, IRXspray Pharma AB (publ)Tel: + 46 (0) 70 767 08 83E-mail: ir@
